ConductScience.org, home

Trial · NCT03120949

Adverse events430

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
seriousLocalised infectionInfections and infestationsTreatment Arm 1: OKZ 64 mg q4w + MTX11,0431
seriousLocalised infectionInfections and infestationsTreatment Arm 2: OKZ 64 mg q2w + MTX01,0610
seriousLower respiratory tract infectionInfections and infestationsTreatment Arm 1: OKZ 64 mg q4w + MTX01,0430
seriousLower respiratory tract infectionInfections and infestationsTreatment Arm 2: OKZ 64 mg q2w + MTX11,0611
seriousLudwig anginaInfections and infestationsTreatment Arm 1: OKZ 64 mg q4w + MTX11,0431
seriousLudwig anginaInfections and infestationsTreatment Arm 2: OKZ 64 mg q2w + MTX01,0610
seriousMedical device site abscessInfections and infestationsTreatment Arm 1: OKZ 64 mg q4w + MTX01,0430
seriousMedical device site abscessInfections and infestationsTreatment Arm 2: OKZ 64 mg q2w + MTX11,0611
seriousNecrotising fasciitisInfections and infestationsTreatment Arm 1: OKZ 64 mg q4w + MTX01,0430
seriousNecrotising fasciitisInfections and infestationsTreatment Arm 2: OKZ 64 mg q2w + MTX11,0611
seriousNecrotising soft tissue infectionInfections and infestationsTreatment Arm 1: OKZ 64 mg q4w + MTX01,0430
seriousNecrotising soft tissue infectionInfections and infestationsTreatment Arm 2: OKZ 64 mg q2w + MTX11,0611
seriousPost procedural infectionInfections and infestationsTreatment Arm 1: OKZ 64 mg q4w + MTX11,0431
seriousPost procedural infectionInfections and infestationsTreatment Arm 2: OKZ 64 mg q2w + MTX01,0610
seriousPulmonary tuberculosisInfections and infestationsTreatment Arm 1: OKZ 64 mg q4w + MTX01,0430
seriousPulmonary tuberculosisInfections and infestationsTreatment Arm 2: OKZ 64 mg q2w + MTX11,0611
seriousRenal abscessInfections and infestationsTreatment Arm 1: OKZ 64 mg q4w + MTX11,0431
seriousRenal abscessInfections and infestationsTreatment Arm 2: OKZ 64 mg q2w + MTX01,0610
seriousSalpingo-oophoritisInfections and infestationsTreatment Arm 1: OKZ 64 mg q4w + MTX11,0431
seriousSalpingo-oophoritisInfections and infestationsTreatment Arm 2: OKZ 64 mg q2w + MTX01,0610

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03120949/events?page=5